Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa
22 juin 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, June 22, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today the submission of a Biologics License...
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
07 juin 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, June 07, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the...
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting
19 mai 2022 19h30 HE
|
Krystal Biotech, Inc.
PITTSBURGH, May 19, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, is pleased to present new data entitled “GEM-3: phase 3...
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational Progress
09 mai 2022 16h15 HE
|
Krystal Biotech, Inc.
Biologics License Application for B-VEC remains on track to file in the US in 2Q 2022 and Marketing Authorization in the EU on track to file in 2H 2022FDA allows dosing at a patient’s home in the Open...
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare Conference
03 mai 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, May 03, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...
Krystal Biotech Announces Home Dosing in B-VEC Open Label Extension Study
11 avr. 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, April 11, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies, today announced that it plans to offer patients with...
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature Medicine
28 mars 2022 11h00 HE
|
Krystal Biotech, Inc.
Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound closure in...
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
26 mars 2022 12h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, presented more detailed results...
Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences
24 mars 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief...
Krystal Biotech to Present at 2022 American Academy of Dermatology Annual Meeting
18 mars 2022 07h00 HE
|
Krystal Biotech, Inc.
PITTSBURGH, March 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present...